https://orcid.org/0000-0001-6831-3044
References
- Hopman RK, DiPersio JF. Advances in stem cell mobilization. Blood Rev. 2014;28(1):31–40. doi:10.1016/j.blre.2014.01.00124476957
- Orciuolo E, Buda G, Marturano E, et al. Lenograstim reduces the incidence of febrile episodes, when compared with Filgrastim, in multiple myeloma patients undergoing stem cell mobilization. Leuk Res. 2011;35(7):899–903. doi:10.1016/j.leukres.2010.10.02921134693
- Gardellini A, Gigli F, Babic A, et al. Filgrastim XM02 (Tevagrastim) after autologous stem cell transplantation compared to lenograstim: favorable cost-efficacy analysis. Ecancermedicalscience. 2013;7:327.23818939
- Rogers KM. Topics in clinical pharmacology: filgrastim, a myeloid colony stimulating factor. Am J Med Sci. 1992;303(6):429–431. doi:10.1097/00000441-199206000-000151376551
- Curran MP, Goa KL. Pegfilgrastim. Drugs. 2002;62(8):1207–1213. doi:10.2165/00003495-200262080-0001212010086
- Baumann I, Testa NG, Lange C, et al. Haemopoietic cells mobilised into the circulation by lenograstim as alternative to bone marrow for allogeneic transplants. Lancet. 1993;341(8841):369. doi:10.1016/0140-6736(93)90166-E
- Guariglia R, Martorelli MC, Telesca D, Milella M, Musto P. Lipegfilgrastim in the management of chemotherapy –induced neutropenia of cancer patients. Biol Targets Ther. 2016;10:1–8.
- Trotta F, Mayer F, Mecozzi A, Amato L, Addis A. Impact of guidance on the prescription patterns of G-CSF for the prevention of febrile neutropenia following anticancer chemotherapy: a population based utilization study in the Lazio Region. BioDrugs. 2017;31(2):117–124. doi:10.1007/s40259-017-0214-928353170
- Sourgens H, Lefrére F. A systematic review of available clinical evidence filgrastim compared with lenograstim. J Clin Pharmacol Ther. 2011;49(8):510–518. doi:10.5414/CP201537
- Innocenti R, Rigacci L, Restelli U, et al. Lenograstim and Filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey. J Blood Med. 2019;10:21–27. doi:10.2147/JBM.S18678630643475
- Wang L, Baser O, Kutikova L, Page JH, Barron R. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized trials. SuppCareCancer. 2015;23:3131–3140.
- Gascon P. Presently available biosimilars in hematology-oncology: G.CSF. Targ Oncol. 2012;7(suppl 1):29–34. doi:10.1007/s11523-011-0190-9
- Schmitt M, Publicover A, Orchard KH, et al. Biosimilar G-CSF based mobilization of peripheral blood hematopoietic stem cells for autologous and allogenic stem cell transplantation. Theranostics. 2014;4(3):280–289. doi:10.7150/thno.775224505236
- Farhan R, Urbanowska E, Zboroboska H, et al. Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors. Ann Hematol. 2017;96:735–739. doi:10.1007/s00277-017-3060-4
- Shaw B, Confer D, William Y, Hwang W, Pamphilon D, Pulsipher M. Concerns about the use of biosimilars granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors position of the World Marrow Donor Association. Haematologica. 2011;96(7):942–947. doi:10.3324/haematol.2011.04574021719883
- Ria R, Reale A, Melaccio A, Racanelli V, Dammacco F, Vacca A. Filgrastim, Lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitors cells in patients with lymphoproliferative malignancies. Clin Exp Med. 2015;15:145–150. doi:10.1007/s10238-014-0282-924722996
- European Group for Blood and Marrow Transplantation (EBMT) 2009 Position statement: biosimilar granulocyte-colony stimulating factor (G-CSF) for stem cell mobilization in related and unrelated donors [cited 227, 2014] Available from: http://www.worldmarrow.org/fileadmin/Committees/CLWG/Biosimilars/Biosimilars_9Jan09.pdf.